Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139(12):1540-1542.
Hidradenitis suppurativa (HS) remains one of the most challenging and humiliating diseases in dermatology. It occurs in 1% to 2% of the population and is categorized into 3 stages. The third stage has very few treatment options, and the most successful to date has been infliximab.1 Since the article by Adams and colleagues, there have been 8 studies looking at the use of infliximab for HS. One of the few double-blind placebo-controlled studies published for any treatment option for HS showed a 50% improvement compared with placebo.2 In my experience, inflixmab infusion is not a cure, but it does offer significant improvement in pain, swelling, and drainage. It also may offer insight into the mechanism of this disabling condition.
From October 2010 to August 2011, this article was accessed 2367 times on the Archives of Dermatology Web site.
Contact Dr Hamzavi at the Department of Dermatology, Center for Multicultural Dermatology, Henry Ford Hospital, 3031 W Grand Blvd, Ste 800, Detroit, MI 48202 (firstname.lastname@example.org).
Hamzavi IH. Top-Accessed Article: Severe Hidradenitis Suppurativa Treated With Infliximab Infusion. Arch Dermatol. 2012;148(7):802. doi:10.1001/archdermatol.2012.542